CU Programme of Idarucizumab for Japanese Patients

NCT02831660 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemorrhage

Interventions

DRUG: idarucizumab

Sponsor

Boehringer Ingelheim